Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR18678-105] to Pentraxin 3/PTX3
  • Suitable for: ICC/IF, Flow Cyt, WB, IP
  • Reacts with: Human

Overview

  • Product name

    Anti-Pentraxin 3/PTX3 antibody [EPR18678-105]
    See all Pentraxin 3/PTX3 primary antibodies

  • Description

    Rabbit monoclonal [EPR18678-105] to Pentraxin 3/PTX3

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    Flow Cyt
    Human
    ICC/IF
    Human
    IP
    Human
    WB
    Human
    See all applications and species data

  • Immunogen

    Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
    (Peptide available as ab85335)

  • Positive control

    • WB: HUVEC whole cell lysate (+/- treatment with LPS and BFA). ICC/IF: HUVEC cells. Flow cytometry: HUVEC cells. IP: HUVEC whole cell lysate.

  • General notes

    Previously labelled as Pentraxin 3. 

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Western blot - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    Western blot - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    All lanes : Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838) at 1/1000 dilution

    Lane 1 : Untreated HUVEC (human umbilical vein endothelial cell line) whole cell lysate
    Lane 2 : HUVEC treated with 0.5 ug/ml LPS for 4 hours followed by 300 ng/ml BFA for 20 hours, whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Developed using the ECL technique.

    Predicted band size: 41 kDa
    Observed band size: 42 kDa
    why is the actual band size different from the predicted?


    Exposure time: 1 second


    Blocking and dilution buffer: 5% NFDM/TBST 

  • Immunocytochemistry/ Immunofluorescence - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    Immunocytochemistry/ Immunofluorescence - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)

    Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (human umbilical vein endothelial cell line) cells labeling Pentraxin 3/PTX3 with ab190838 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining on HUVEC cell line.

    The nuclear counterstain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) secondary antibody at 1/200 dilution (red).


    -ve control: PBS only, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

     

  • Western blot - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    Western blot - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838) at 1/200 dilution + HUVEC (human umbilical vein endothelial cell line) whole cell lysate at 20 µg

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Developed using the ECL technique.

    Predicted band size: 41 kDa
    Observed band size: 42 kDa why is the actual band size different from the predicted?


    Exposure time: 1 minute


    Blocking and dilution buffer: 5% NFDM/TBST

    Higher concentration of this antibody is required for the detection of Pentraxin 3/PTX3 in untreated cells in WB.

  • Flow Cytometry - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    Flow Cytometry - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)

    Flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol-permeabilized HUVEC (human umbilical vein endothelial cell line) cells labeling Pentraxin 3/PTX3 with ab190838 at 1/60 dilution (red) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077), at 1/2000 dilution was used as the secondary antibody.

  • Immunoprecipitation - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    Immunoprecipitation - Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)

    Pentraxin 3/PTX3 was immunoprecipitated from 0.35 mg of HUVEC (human umbilical vein endothelial cell line) whole cell lysate with ab190838 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab190838 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.


    Lane 1: HUVEC whole cell lysate 10 μg (Input).
    Lane 2: ab190838 IP in HUVEC whole cell lysate.
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab190838 in HUVEC whole cell lysate.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.
    Exposure time: 3 minutes.

    The molecular weight observed is consistent with what has been described in the literature (PMID: 17389238).

  • Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)
    Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-Pentraxin 3/PTX3 antibody [EPR18678-105] (ab190838)

© 2021 Astana Biomed Group LLP. All rights reserved.